Who this treatment is for — and who it isn't

Could a ChondroFiller injection treat my wrist damage? For many patients the honest answer is: it depends on the type of damage, not simply the degree of pain.

Wrist cartilage problems broadly divide into two categories. The first is a focal defect — a discrete, localised patch of damaged or missing cartilage, most often arising from a distal radius fracture, a fall onto an outstretched hand, or ligament injury that leaves an area of exposed bone within an otherwise intact joint. The second is diffuse osteoarthritic wear, where thinning is widespread across the joint surface. ChondroFiller injection is designed for the first category.

In structural terms, the procedure is best suited to isolated lesions graded ICRS II–III — meaning partial to full-thickness cartilage loss in a contained area. The collagen scaffold used covers defects up to approximately 3 cm², with clinical evaluation data extending feasibility to 6 cm². Practically, that describes a localised patch rather than a joint that is worn throughout.

Common routes to this diagnosis include persistent wrist pain and reduced grip strength after a fracture or fall, cartilage damage identified on MRI when other injuries are being investigated, or early-stage trapeziometacarpal (thumb-base) osteoarthritis where the damage remains focal.

Patients with advanced, bone-on-bone changes across the wrist joint are outside the scope of regenerative scaffold repair; they need a separate conversation about joint preservation or replacement surgery.

Age alone is not a disqualifying factor. The treatment works by drawing the patient's own progenitor cells into the scaffold, so defect characteristics and underlying joint biology carry more weight than a date of birth. The following section explains how that process works.

How the scaffold works once it's injected

Unlike a steroid or hyaluronic acid injection, ChondroFiller does not simply dampen inflammation or lubricate the joint — it provides a physical structure that the body uses to build new cartilage tissue.

The product is an acellular Type I collagen solution: it contains no donor cells, no growth factors, and no living biological material. What it contains is a precisely formulated matrix derived from murine collagen that, on contact with the fluid environment inside the joint, self-gels within minutes. The result is a stable, porous scaffold that conforms to and fills the defect — sitting within the damage rather than floating loose in the joint space.

The scaffolding analogy is deliberate. Once the gel sets, it acts in a similar way to a construction frame: it creates an organised, hospitable structure that the body's own repair cells can inhabit and use. Mesenchymal progenitor cells — stem cells already present in the surrounding synovial tissue and subchondral bone — detect chemical signals from the collagen matrix and migrate into it. Inside the scaffold, those cells gradually differentiate into chondrocytes, the specialised cells responsible for producing cartilage. Over time, they begin laying down new cartilage matrix around themselves.

As the repair tissue matures, the collagen scaffold degrades naturally. Nothing permanent remains implanted — the aim is host-derived repair tissue that the body has built for itself, supported and directed by the temporary scaffold.

This mechanism is why the injection can be delivered under ultrasound guidance into a narrow joint such as the wrist, without requiring surface debridement or a dry operative field. The collagen is administered in liquid form into the fluid joint environment and gels in place — an additive approach that preserves the surrounding cartilage structures rather than disturbing them.

What the clinical evidence shows for wrist joints

Two prospective clinical studies provide the most direct evidence for ChondroFiller in the wrist and its adjacent small joints.

The strongest wrist-specific data comes from Matta et al., who evaluated ChondroFiller Liquid in patients with focal cartilage defects arising from intra-articular distal radius fractures — the most common mechanism of focal wrist cartilage damage. That study used arthroscopic delivery during open reduction and internal fixation (ORIF), via fine G20–21 cannulas under dry-field conditions; this is cited here as evidence of structural and clinical efficacy in the wrist, not as the current outpatient pathway. Follow-up MRI confirmed reduced bone marrow oedema, diminished periarticular effusion, and visible widening of the joint space. Clinical measures showed meaningful NRS pain reduction, improved DASH disability scores, and increased grip and pincer strength on Jamar and pinch testing.

The second anchor is Corain et al. (2023), a prospective study of 43 patients with trapeziometacarpal osteoarthritis — the thumb-base joint — treated by single intra-articular infiltration under fluoroscopic guidance. Across Eaton-Littler stages I–IV, both early and advanced groups achieved highly significant improvements in NRS pain, DASH function, and grip and pincer strength at 30 days and six months post-injection. The same outcome metrics align well with the Matta findings, extending the evidence to the anatomically adjacent small joints of the wrist complex.

In broader context, over 19,000 ChondroFiller cases have been completed worldwide. Across joints, IKDC scores have improved by approximately 30 points in the knee, Harris Hip Score by 33 points in the hip, and MOCART cartilage regeneration scores have reached 70–87. The wrist-specific NRS and DASH trajectories sit within those patterns. The complaint rate across all joints is approximately 0.06% — a reassuring safety signal at scale.

The evidence gap is worth stating plainly. Wrist data is narrower than for the knee or hip, and the Matta study used a surgical delivery route in the context of fracture fixation. The standalone ultrasound-guided injection pathway extrapolates from the product's mechanism, the adjacent-joint findings from Corain, and the consistent efficacy seen across multiple joints globally — a coherent, if still developing, clinical picture.

How the injection is carried out

On the day of treatment, patients arrive at the London Cartilage Clinic on Harley Street as outpatients. There is no general anaesthetic, no theatre booking, and no overnight stay — the entire appointment, including consultation and the injection itself, is completed within a single session.

Before the collagen scaffold is introduced, an intravenous antibiotic is administered as a precautionary measure; this is included as standard in the treatment package. The wrist is then prepared for image-guided needle placement. Because the radiocarpal joint is narrow and the target zone for a focal defect is small, ultrasound guidance is used throughout: the clinician confirms needle position in real time before any material is released, ensuring the scaffold reaches the defect rather than the surrounding tissue.

The injection itself takes only a few minutes. Once the liquid collagen enters the joint environment, it self-gels in place — as described in the previous section — so there is no waiting for a material to set externally or any need to immobilise the wrist immediately during the procedure.

Professor Paul Y.F. Lee, who leads ChondroFiller delivery at the clinic, has noted that consistent image-guided placement is central to how well the scaffold integrates with the defect. The same product can produce different results depending on how accurately it is positioned, which is why technique and experience with wrist anatomy matter at this stage.

Most patients are able to leave the clinic shortly after the procedure. Specific guidance on wrist loading and return to activity in the weeks that follow is provided at the included six-week review appointment.

Costs, insurance, and the dual-injection option

The ChondroFiller injection for the wrist starts from £3,000 per treatment. That figure is inclusive: consultation, ultrasound imaging, the collagen scaffold itself, the injection, intravenous antibiotic prophylaxis, and the six-week follow-up review are all covered within the package price. Clinical complexity can affect the final cost, so confirming the current figure directly with the London Cartilage Clinic before booking is advisable.

Insurance

Private medical insurers do fund ChondroFiller in some cases. The procedure is billed in the UK under CCSD codes W3111 (cartilage regeneration with collagen scaffold) and W8500. Claims are most commonly approved by Bupa, Aviva, and WPA, though outcomes vary by policy. Written pre-authorisation must be obtained before the appointment — insurers will not typically reimburse retrospectively.

The dual-injection option for more advanced OA

For patients where cartilage loss has also led to significant joint-space narrowing, a combined protocol pairing ChondroFiller with Arthrosamid is available at approximately £6,000. The two products serve distinct roles: ChondroFiller acts as the regenerative scaffold, promoting new cartilage formation; Arthrosamid is a stable polyacrylamide hydrogel that provides mechanical cushioning within the synovial lining. This is combination therapy targeting two different aspects of the same joint — not a single blended product.

Patients unsure which pathway fits their wrist can discuss both options at an assessment with the London Cartilage Clinic on Harley Street.

Getting an assessment at the London Cartilage Clinic

The London Cartilage Clinic on Harley Street is the UK's certified delivery centre for ChondroFiller, and the wrist is among the joints its team assesses routinely.

An initial consultation focuses on establishing suitability before any treatment is planned. The clinician will review existing MRI or imaging, assess the size and location of the defect, and confirm whether the focal-defect criteria that make ChondroFiller appropriate are met. Patients whose damage does not fit the profile — whether because the lesion is too diffuse, the joint too degenerate, or another pathway is more appropriate — will be told clearly and directed accordingly.

Referrals from GPs, physiotherapists, and orthopaedic surgeons are welcome; patients may also self-refer.

To book an assessment, visit londoncartilage.com.

1. [1] Wrist. https://en.wikipedia.org/?curid=234901 https://en.wikipedia.org/?curid=234901